FDA creates New Advisory Committee for Evaluation of Genetic Metabolic Disease Treatments (from Catapult’s regulatory round-up – December 2023)
The purpose of the new Committee is to review and evaluate data on the safety and effectiveness of marketed and investigational human drug and biologic products for use in the treatment of genetic metabolic diseases and makes appropriate recommendations to the Commissioner of Food and Drugs. Please find further details here.
Published on the 5th of January 2024. Read the entire regulatory round-up for December 2023 here.
OpenEdition vous propose de citer ce billet de la manière suivante :
adelage (7 août 2024). FDA creates New Advisory Committee for Evaluation of Genetic Metabolic Disease Treatments (from Catapult’s regulatory round-up – December 2023). ELSIBI. Consulté le 16 janvier 2025 à l’adresse https://doi.org/10.58079/1258p
